Last reviewed: June 24, 2026
Last updated: June 24, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide medications like Wegovy have transformed weight loss treatment for millions of people, but they are not appropriate for everyone. Understanding which patients should avoid GLP-1 therapy—and why—is essential for safe, effective weight management. PlexusDx provides personalized guidance to help you determine if GLP-1 treatment is right for your health profile.
Medical Conditions That Contraindicate GLP-1 Use
Several serious health conditions make GLP-1 receptor agonists, including Wegovy, medically unsafe. Patients with a personal or family history of medullary thyroid carcinoma should never use semaglutide, as the drug has been shown to increase thyroid C-cell tumors in animal studies. Additionally, those with multiple endocrine neoplasia syndrome type 2 (MEN2)—a genetic disorder affecting hormone-producing glands—must avoid GLP-1 medications entirely.
Severe pancreatitis history is another critical exclusion. Patients who have experienced acute pancreatitis or chronic pancreatitis face elevated risk of recurrence if they take GLP-1 drugs, which stimulate pancreatic hormone release. Uncontrolled diabetic ketoacidosis and severe kidney disease also warrant careful medical review before starting therapy, as semaglutide may worsen metabolic stability or renal function depending on baseline status.
Pregnancy, Breastfeeding, and Fertility Concerns
Women who are pregnant or planning to become pregnant should discontinue GLP-1 therapy at least two months before attempting conception, as animal studies indicate potential effects on fetal development. The exact human risks remain incompletely characterized, but the pharmaceutical principle of caution applies: if pregnancy is planned, GLP-1 use should pause under medical supervision. Breastfeeding mothers similarly lack sufficient safety data and are advised to avoid semaglutide while nursing.
Beyond pregnancy, some patients experience changes in ovulation or menstrual regularity on GLP-1 drugs—partly due to rapid weight loss itself. Those actively trying to conceive should discuss timing with their doctor, as birth control effectiveness may increase during weight loss. PlexusDx clinicians review fertility status during initial assessment to ensure safe, appropriate treatment planning for this population.
Diabetic Retinopathy and Rapid Blood Sugar Changes
Patients with diabetic retinopathy (damage to blood vessels in the eye from diabetes) must approach GLP-1 therapy with extreme caution. Sudden, aggressive blood sugar lowering—especially in people already taking insulin or other glucose-lowering drugs—can temporarily worsen vision as fluid shifts in the eye. This does not mean GLP-1 is absolutely forbidden for retinopathy patients, but dose escalation must be gradual and coordinated with ophthalmology and endocrinology.
Similarly, those taking multiple diabetes medications face higher hypoglycemia (low blood sugar) risk when adding semaglutide. Insulin doses often need downward adjustment to prevent dangerous drops in glucose. Close monitoring during the first weeks of treatment is non-negotiable, and dose changes should be individualized based on continuous glucose monitoring or fingerstick readings, not on generic protocols.
Medication Interactions and Gastrointestinal Surgery History
Certain medications interact problematically with GLP-1 drugs. Oral diabetes medications—particularly sulfonylureas and meglitinides—significantly increase hypoglycemia risk when combined with semaglutide and typically require dose reduction or discontinuation. Additionally, GLP-1 slows gastric emptying, which can delay absorption of oral medications, including some birth control pills and warfarin (a blood thinner). Patients on warfarin must have INR levels monitored closely if starting GLP-1 therapy.
Patients with a history of gastrointestinal bypass surgery, gastric banding, or other bariatric procedures require special consideration. GLP-1 drugs can exacerbate nausea, vomiting, and dumping syndrome in post-bariatric patients, and the combination of reduced gastric capacity plus further appetite suppression may lead to severe nutritional deficiency. A thorough surgical history is essential before treatment initiation, and oral formulations may be safer than injections in some cases.
Thyroid Disease, Dehydration Risk, and Gallbladder Issues
Patients with medullary thyroid cancer or MEN2 are absolute contraindications (covered above), but those with other thyroid conditions merit attention too. People on levothyroxine for hypothyroidism may experience variable absorption if GLP-1 slows digestion, potentially requiring thyroid function monitoring and dose adjustment. Additionally, rapid weight loss itself can affect thyroid hormone levels, necessitating repeat testing after two to three months on therapy.
Dehydration is an underestimated risk with GLP-1 use, especially in warm climates or with high activity levels. Nausea and appetite suppression reduce fluid intake at the same time that weight loss increases overall metabolic demands for hydration. Patients with a prior history of kidney stones or chronic dehydration should drink extra fluids and may need electrolyte monitoring. Finally, those with pre-existing gallstones or gallbladder disease face increased risk of gallstone-related complications during rapid weight loss, as bile composition changes and stone formation accelerates; prophylactic ursodeoxycholic acid may be considered in high-risk individuals.
How PlexusDx Personalizes Safety Screening
PlexusDx uses a comprehensive health questionnaire and optional Precision Peptide Genetic Test to identify whether you are a suitable candidate for GLP-1 therapy. The genetic test analyzes key variants in the GLP1R, GIPR, FTO, and MC4R genes—markers linked to GLP-1 responsiveness and metabolic risk factors. This personalized data helps PlexusDx clinicians predict who will benefit most and who should avoid therapy altogether.
Once deemed appropriate for treatment, PlexusDx offers multiple compounded semaglutide options—injection or oral—from licensed 503A pharmacies, starting at just $149 per month. If standard semaglutide is not ideal for your profile, PlexusDx also provides tirzepatide (a dual GLP-1/GIP agonist) and combination therapies. Your dose may need to go up as your body adapts, but your price won't change, ensuring predictable, affordable weight loss support without insurance requirements or membership fees.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the most common reason someone should not take Wegovy or semaglutide?
Personal or family history of medullary thyroid carcinoma is the strongest absolute contraindication, as semaglutide increases thyroid C-cell tumors in animal models. Patients with MEN2 syndrome must also avoid GLP-1 drugs entirely. Your doctor will review your full medical history during screening.
Can I take Wegovy if I have Type 2 diabetes and take insulin?
You can take semaglutide with insulin, but your insulin dose must be reduced significantly to prevent dangerous low blood sugar. Close monitoring and frequent glucose checks are essential during the first weeks. PlexusDx clinicians coordinate insulin adjustments carefully before and after starting GLP-1 therapy.
Is it safe to take GLP-1 if I am trying to get pregnant?
No. Women planning pregnancy should stop semaglutide at least two months before conception, as animal studies show potential fetal effects. Once pregnant or breastfeeding, GLP-1 therapy is not recommended. PlexusDx can discuss timing and alternative weight loss strategies if fertility is a near-term goal.
What happens if I have gallstones and want to take semaglutide?
Rapid weight loss—accelerated by GLP-1—increases gallstone formation risk in susceptible people. If you have existing gallstones, your doctor may recommend slower weight loss, increased hydration, or a medication called ursodeoxycholic acid to protect your gallbladder. Pre-screening ultrasound may be wise.
How does the PlexusDx Precision Peptide Genetic Test help identify safety concerns?
The test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes that influence how your body responds to GLP-1 drugs and metabolic risk markers. Combined with your medical history, this genetic insight helps PlexusDx predict whether you'll respond well and safely to semaglutide, tirzepatide, or a personalized combination at just $99 after your first month of treatment.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
When Do Ozempic Side Effects Start After Injection?
Navigating Your Health: Can I Take Antibiotics with Wegovy?